O	0	14	Downregulation	Downregulation	NN	B-NP
O	15	17	of	of	IN	B-PP
O	18	19	c	c	NN	B-NP
O	19	20	-	-	HYPH	O
O	20	24	FLIP	FLIP	NN	B-NP
O	25	35	sensitizes	sensitize	VBZ	B-VP
B-Cell	36	41	DU145	DU145	NN	B-NP
I-Cell	42	50	prostate	prostate	NN	I-NP
I-Cell	51	57	cancer	cancer	NN	I-NP
I-Cell	58	63	cells	cell	NNS	I-NP
O	64	66	to	to	TO	B-PP
O	67	70	Fas	Fas	NN	B-NP
O	70	71	-	-	HYPH	O
O	71	79	mediated	mediate	VBN	B-NP
O	80	89	apoptosis	apoptosis	NN	I-NP
O	89	90	.	.	.	O

O	92	100	Although	Although	IN	B-SBAR
B-Cell	101	106	DU145	DU145	NN	B-NP
I-Cell	107	115	prostate	prostate	NN	I-NP
I-Cell	116	122	cancer	cancer	NN	I-NP
I-Cell	123	128	cells	cell	NNS	I-NP
O	129	132	are	be	VBP	B-VP
O	133	142	resistant	resistant	JJ	B-ADJP
O	143	145	to	to	TO	B-PP
O	146	157	exogenously	exogenously	RB	B-NP
O	158	165	applied	apply	VBN	I-NP
O	166	169	Fas	Fas	NN	I-NP
O	170	177	agonist	agonist	NN	I-NP
O	178	180	CH	CH	NN	I-NP
O	180	181	-	-	HYPH	B-NP
O	181	183	11	11	CD	I-NP
O	184	185	(	(	(	O
O	185	189	anti	anti	AFX	O
O	189	190	-	-	HYPH	B-NP
O	190	193	Fas	Fas	NN	I-NP
O	194	204	monoclonal	monoclonal	JJ	I-NP
O	205	213	antibody	antibody	NN	I-NP
O	213	214	)	)	)	O
O	214	215	,	,	,	O
O	216	219	Fas	Fas	NN	B-NP
O	219	220	-	-	HYPH	B-NP
O	220	230	resistance	resistance	NN	I-NP
O	231	234	can	can	MD	B-VP
O	235	237	be	be	VB	I-VP
O	238	246	overcome	overcome	VBN	I-VP
O	247	252	using	use	VBG	B-VP
O	253	254	a	a	DT	B-NP
O	255	259	FasL	FasL	NN	I-NP
O	260	270	expressing	express	VBG	B-VP
O	271	281	adenovirus	adenovirus	NN	B-NP
O	282	283	(	(	(	O
O	283	292	AdGFPFasL	AdGFPFasL	NN	B-NP
O	292	293	(	(	(	O
O	293	296	TET	TET	NN	B-NP
O	296	297	)	)	)	O
O	297	298	)	)	)	O
O	299	300	[	[	(	O
O	300	304	Hyer	Hyer	NNP	B-NP
O	305	307	et	et	FW	I-NP
O	308	310	al	al	FW	I-NP
O	310	311	.	.	FW	I-NP
O	311	312	,	,	,	O
O	313	322	Molecular	Molecular	NNP	B-NP
O	323	330	Therapy	Therapy	NNP	I-NP
O	330	331	,	,	,	O
O	332	336	2000	2000	CD	B-NP
O	336	337	;	;	:	O
O	338	339	2	2	CD	B-NP
O	339	340	:	:	:	O
O	340	343	348	348	CD	B-NP
O	343	344	-	-	HYPH	I-NP
O	344	346	58	58	CD	I-NP
O	347	348	(	(	(	O
O	348	351	ref	ref	NN	B-NP
O	351	352	.	.	.	O
O	352	354	12	12	CD	O
O	354	355	)	)	)	O
O	355	356	]	]	)	O
O	356	357	.	.	.	O

O	358	361	The	The	DT	B-NP
O	362	369	purpose	purpose	NN	I-NP
O	370	372	of	of	IN	B-PP
O	373	377	this	this	DT	B-NP
O	378	383	study	study	NN	I-NP
O	384	387	was	be	VBD	B-VP
O	388	390	to	to	TO	I-VP
O	391	394	try	try	VB	I-VP
O	395	397	to	to	TO	I-VP
O	398	408	understand	understand	VB	I-VP
O	409	412	why	why	WRB	B-ADVP
B-Cell	413	418	DU145	DU145	NN	B-NP
I-Cell	419	424	cells	cell	NNS	I-NP
O	425	428	are	be	VBP	B-VP
O	429	438	resistant	resistant	JJ	B-ADJP
O	439	441	to	to	TO	B-PP
O	442	444	CH	CH	NN	B-NP
O	444	445	-	-	HYPH	B-NP
O	445	447	11	11	CD	I-NP
O	448	451	and	and	CC	O
O	452	461	determine	determine	VB	B-VP
O	462	465	the	the	DT	B-NP
O	466	475	signaling	signaling	NN	I-NP
O	476	483	pathway	pathway	NN	I-NP
O	484	492	utilized	utilize	VBN	B-VP
O	493	495	by	by	IN	B-PP
O	496	505	AdGFPFasL	AdGFPFasL	NN	B-NP
O	505	506	(	(	(	O
O	506	509	TET	TET	NN	B-NP
O	509	510	)	)	)	O
O	511	513	to	to	TO	B-VP
O	514	520	induce	induce	VB	I-VP
O	521	530	apoptosis	apoptosis	NN	B-NP
O	531	533	in	in	IN	B-PP
O	534	539	these	these	DT	B-NP
O	540	543	Fas	Fas	NN	I-NP
O	543	544	-	-	HYPH	B-NP
O	544	553	resistant	resistant	JJ	I-NP
B-Cell	554	559	cells	cell	NNS	I-NP
O	559	560	.	.	.	O

O	561	566	Using	Use	VBG	B-VP
O	567	577	immunoblot	immunoblot	NN	B-NP
O	578	586	analysis	analysis	NN	I-NP
O	586	587	,	,	,	O
O	588	590	we	we	PRP	B-NP
O	591	595	show	show	VBP	B-VP
O	596	600	that	that	IN	B-SBAR
O	601	610	AdGFPFasL	AdGFPFasL	NN	B-NP
O	610	611	(	(	(	O
O	611	614	TET	TET	NN	B-NP
O	614	615	)	)	)	O
O	616	618	is	be	VBZ	B-VP
O	619	626	capable	capable	JJ	B-ADJP
O	627	629	of	of	IN	B-PP
O	630	640	initiating	initiate	VBG	B-VP
O	641	644	the	the	DT	B-NP
O	645	652	classic	classic	JJ	I-NP
O	653	656	Fas	Fas	NN	I-NP
O	656	657	-	-	HYPH	B-VP
O	657	665	mediated	mediate	VBN	B-NP
O	666	675	apoptotic	apoptotic	JJ	I-NP
O	676	683	pathway	pathway	NN	I-NP
O	684	686	in	in	IN	B-PP
B-Cell	687	692	DU145	DU145	NN	B-NP
I-Cell	693	698	cells	cell	NNS	I-NP
O	698	699	,	,	,	O
O	700	705	which	which	WDT	B-NP
O	706	714	includes	include	VBZ	B-VP
O	715	725	activation	activation	NN	B-NP
O	726	728	of	of	IN	B-PP
O	729	737	caspases	caspas	NNS	B-NP
O	737	738	-	-	HYPH	O
O	738	739	8	8	CD	B-NP
O	739	740	,	,	,	O
O	741	742	-	-	HYPH	B-NP
O	742	743	3	3	CD	I-NP
O	743	744	,	,	,	O
O	745	746	-	-	HYPH	B-NP
O	746	747	7	7	CD	I-NP
O	747	748	,	,	,	O
O	749	752	and	and	CC	O
O	753	754	-	-	HYPH	B-NP
O	754	755	9	9	CD	I-NP
O	755	756	,	,	,	O
O	757	760	BID	BID	NN	B-NP
O	761	769	cleavage	cleavage	NN	I-NP
O	769	770	,	,	,	O
O	771	781	cytochrome	cytochrome	NN	B-NP
O	782	783	c	c	NN	I-NP
O	784	791	release	release	NN	I-NP
O	792	796	from	from	IN	B-PP
B-Cellular_component	797	809	mitochondria	mitochondrion	NNS	B-NP
O	809	810	,	,	,	O
O	811	814	and	and	CC	O
O	815	819	PARP	PARP	NN	B-NP
O	820	828	cleavage	cleavage	NN	I-NP
O	828	829	.	.	.	O

O	830	832	In	In	IN	B-PP
O	833	841	contrast	contrast	NN	B-NP
O	841	842	,	,	,	O
O	843	845	CH	CH	NN	B-NP
O	845	846	-	-	HYPH	O
O	846	848	11	11	CD	B-NP
O	849	854	binds	bind	VBZ	B-VP
O	855	857	to	to	TO	B-PP
O	858	861	Fas	Fas	NN	B-NP
O	861	862	,	,	,	O
O	863	866	but	but	CC	O
O	867	869	is	be	VBZ	B-VP
O	870	876	unable	unable	JJ	B-ADJP
O	877	879	to	to	TO	B-VP
O	880	888	transmit	transmit	VB	I-VP
O	889	892	the	the	DT	B-NP
O	893	898	death	death	NN	I-NP
O	899	905	signal	signal	NN	I-NP
O	906	912	beyond	beyond	IN	B-PP
O	913	916	the	the	DT	B-NP
B-Cellular_component	917	923	plasma	plasma	NN	I-NP
I-Cellular_component	924	932	membrane	membrane	NN	I-NP
O	933	943	suggesting	suggest	VBG	B-VP
O	944	945	a	a	DT	B-NP
O	946	951	block	block	NN	I-NP
O	952	954	at	at	IN	B-PP
O	955	958	the	the	DT	B-NP
O	959	963	DISC	DISC	NN	I-NP
O	964	965	(	(	(	O
O	965	970	death	death	NN	B-NP
O	971	979	inducing	induce	VBG	B-VP
O	980	989	signaling	signaling	NN	B-NP
O	990	997	complex	complex	NN	I-NP
O	997	998	)	)	)	O
O	998	999	.	.	.	O

O	1000	1003	The	The	DT	B-NP
O	1004	1008	anti	anti	AFX	I-NP
O	1008	1009	-	-	HYPH	I-NP
O	1009	1018	apoptotic	apoptotic	JJ	I-NP
O	1019	1026	protein	protein	NN	I-NP
O	1027	1028	c	c	NN	I-NP
O	1028	1029	-	-	HYPH	B-NP
O	1029	1033	FLIP	FLIP	NN	I-NP
O	1034	1035	(	(	(	O
O	1035	1043	cellular	cellular	JJ	B-NP
O	1044	1049	Flice	Flice	NN	I-NP
O	1049	1050	-	-	HYPH	B-NP
O	1050	1054	like	like	JJ	I-NP
O	1055	1065	inhibitory	inhibitory	JJ	I-NP
O	1066	1073	protein	protein	NN	I-NP
O	1073	1074	)	)	)	O
O	1074	1075	,	,	,	O
O	1076	1081	which	which	WDT	B-NP
O	1082	1085	has	have	VBZ	B-VP
O	1086	1090	been	be	VBN	I-VP
O	1091	1096	shown	show	VBN	I-VP
O	1097	1099	to	to	TO	I-VP
O	1100	1107	inhibit	inhibit	VB	I-VP
O	1108	1111	Fas	Fas	NN	B-NP
O	1111	1112	-	-	HYPH	O
O	1112	1120	mediated	mediate	VBN	B-NP
O	1121	1130	apoptosis	apoptosis	NN	I-NP
O	1131	1133	at	at	IN	B-PP
O	1134	1137	the	the	DT	B-NP
O	1138	1142	DISC	DISC	NNP	I-NP
O	1142	1143	,	,	,	O
O	1144	1147	was	be	VBD	B-VP
O	1148	1152	down	down	RB	B-ADVP
O	1152	1153	-	-	HYPH	B-ADJP
O	1153	1162	regulated	regulate	VBN	B-VP
O	1163	1172	following	follow	VBG	B-PP
O	1173	1182	AdGFPFasL	AdGFPFasL	NN	B-NP
O	1182	1183	(	(	(	O
O	1183	1186	TET	TET	NN	B-NP
O	1186	1187	)	)	)	O
O	1188	1197	treatment	treatment	NN	B-NP
O	1198	1207	prompting	prompt	VBG	B-VP
O	1208	1210	us	us	PRP	B-NP
O	1211	1213	to	to	TO	B-VP
O	1214	1225	investigate	investigate	VB	I-VP
O	1226	1229	its	its	PRP$	B-NP
O	1230	1234	role	role	NN	I-NP
O	1235	1237	in	in	IN	B-PP
O	1238	1248	inhibiting	inhibit	VBG	B-VP
O	1249	1251	CH	CH	NN	B-NP
O	1251	1252	-	-	HYPH	B-NP
O	1252	1254	11	11	CD	I-NP
O	1254	1255	-	-	HYPH	I-NP
O	1255	1262	induced	induce	VBN	I-NP
B-Cell	1263	1267	cell	cell	NN	I-NP
O	1268	1273	death	death	NN	I-NP
O	1273	1274	.	.	.	O

O	1275	1280	Using	Use	VBG	B-VP
O	1281	1282	c	c	NN	B-NP
O	1282	1283	-	-	HYPH	I-NP
O	1283	1287	FLIP	FLIP	NN	I-NP
O	1288	1292	anti	anti	AFX	O
O	1292	1293	-	-	HYPH	B-NP
O	1293	1298	sense	sense	NN	I-NP
O	1299	1315	oligonucleotides	oligonucleotide	NNS	I-NP
O	1316	1318	to	to	TO	B-VP
O	1319	1323	down	down	RB	I-VP
O	1323	1324	-	-	HYPH	I-VP
O	1324	1332	regulate	regulate	VB	I-VP
O	1333	1334	c	c	SYM	B-NP
O	1334	1335	-	-	:	O
O	1335	1339	FLIP	FLIP	NN	B-NP
O	1340	1342	we	we	PRP	B-NP
O	1343	1353	sensitized	sensitize	VBD	B-VP
B-Cell	1354	1359	DU145	DU145	NN	B-NP
I-Cell	1360	1365	cells	cell	NNS	I-NP
O	1366	1368	to	to	TO	B-PP
O	1369	1371	CH	CH	NN	B-NP
O	1371	1372	-	-	HYPH	B-NP
O	1372	1374	11	11	CD	I-NP
O	1374	1375	-	-	HYPH	I-NP
O	1375	1382	induced	induce	VBN	I-NP
O	1383	1392	apoptosis	apoptosis	NN	I-NP
O	1392	1393	.	.	.	O

O	1394	1399	These	These	DT	B-NP
O	1400	1404	data	datum	NNS	I-NP
O	1405	1412	suggest	suggest	VBP	B-VP
O	1413	1417	that	that	IN	B-SBAR
O	1418	1419	c	c	NN	B-NP
O	1419	1420	-	-	HYPH	B-NP
O	1420	1424	FLIP	FLIP	NN	I-NP
O	1425	1428	may	may	MD	B-VP
O	1429	1433	play	play	VB	I-VP
O	1434	1435	a	a	DT	B-NP
O	1436	1444	critical	critical	JJ	I-NP
O	1445	1449	role	role	NN	I-NP
O	1450	1452	in	in	IN	B-PP
O	1453	1463	regulating	regulate	VBG	B-VP
O	1464	1467	Fas	Fas	NN	B-NP
O	1467	1468	-	-	HYPH	O
O	1468	1476	mediated	mediate	VBN	B-NP
O	1477	1486	apoptosis	apoptosis	NN	I-NP
O	1487	1489	in	in	IN	B-PP
B-Cell	1490	1498	prostate	prostate	NN	B-NP
I-Cell	1499	1505	cancer	cancer	NN	I-NP
I-Cell	1506	1511	cells	cell	NNS	I-NP
O	1512	1515	and	and	CC	O
O	1516	1520	that	that	IN	B-SBAR
O	1521	1531	modulation	modulation	NN	B-NP
O	1532	1534	of	of	IN	B-PP
O	1535	1536	c	c	NN	B-NP
O	1536	1537	-	-	HYPH	I-NP
O	1537	1541	FLIP	FLIP	NN	I-NP
O	1542	1545	may	may	MD	B-VP
O	1546	1553	enhance	enhance	VB	I-VP
O	1554	1557	Fas	Fas	NN	B-NP
O	1558	1567	signaling	signaling	NN	I-NP
O	1568	1573	based	based	JJ	I-NP
O	1574	1583	therapies	therapy	NNS	I-NP
O	1583	1584	.	.	.	O

